You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Path to Commercialization ofthe first "off the shelf" T cell product

    SBC: ViraCyte LLC            Topic: NHLBI

    ABSTRACT The adoptive transfer of virus specific T cells has produced remarkable clinical results in patients with viral diseaseHoweverbroader implementation of this therapy has been limited by theiprohibitive production costsiicomplexity of manufactureiiiprolonged time for preparation and product releaseandivthe requirement for individualizedpatient specific productsOver the pastyears we have sys ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Validation of a Novel Fungicidal Approach for Cryptococcal Meningitis

    SBC: Minnetronix Medical, Inc.            Topic: NIAID

    ABSTRACT When Cryptococcus is manifested as cryptococcal meningitis (CM), it creates a large burden of mortality and morbidity to the patient and is very difficult for the clinician to treat. There are now an estimated 2600-7800 US cases and 400,000 cases of CM worldwide annually, with estimated mortality of 15-50% per year. CM is caused when Cryptococcus neoformans, a basidiomycete fungal pathoge ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Stroke Treatment by Chemically-induced Hypothermia

    SBC: JT Pharmaceuticals, Inc.            Topic: 100

    ABSTRACTWhile acute stroke is a leading cause of human death and disability in the United Statesunfortunatelyclinical therapies for stroke are limited and unsatisfactoryThe overwhelming failures of stroke treatments in clinical trials strongly indicate thatto battle this multifaceted brain disordernovel strategies that target multiple cell types and afford different mechanisms of protection are ne ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II

    SBC: TRANSLATIONAL SCIENCES INC            Topic: NHLBI

    This SBIR Application is responsive to NHLBI Small Business Topics of Special Interest (therapeutics) that are of high programmatic interest (HLS-17-04). Hemorrhage or bleeding is a serious or fatal complication of surgery. Antifibrinolytic agents that inhibit plasmin-mediated fibrinolysis can significantly reduce blood loss, emergency reoperation, morbidity and death in patients with severe hemor ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. An HXYZ-g HR-Fast-MAS probe for Dramatically Improved Biomolecular Structure Determinations

    SBC: DOTY SCIENTIFIC, INC.            Topic: 400

    An HXYZ g HR Fast MAS probe for Dramatically Improved Biomolecular Structure Determinations AbstractLiquid state NMR spectroscopy is arguably one of the best tools for structure determination for soluble proteinsThe method provides atomic resolution for modest molecular weight proteins and or their complexesThe method begins to have difficulty when the molecular weight of the system causes slow mo ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents

    SBC: BIOVENTURES, INC            Topic: 172

    Because of its high sensitivitypolymerase chain reactionPCRis the gold standard for the diagnosis of many infectious diseasesbut generally only implemented in well equipped laboratoriesOne of the major roadblocks for expanding PCR to point of care markets is the lack of simplerobustsingle tube PCR designs which preserve its laboratory based high sensitivity and specificityIn this Fast Track STTR a ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Modeling Disease in Swine by Transplantation of Gene Targeted Germ Cells

    SBC: Recombinetics, Inc.            Topic: 400

    PROJECT SUMMARY Swine are important in biomedical research for the study of human diseases that are poorly recapitulated by rodent speciesfor the development and testing of preclinical therapeutics in humanized disease models and as potential sources of xenogeneic or allogeneic organs and tissuesHoweverthe creation and propagation of biomedical swine is plagued by inefficiencies related to animal ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Targeting DNA damage response pathways for the treatment of advanced lung cancer

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: 102

    ABSTRACTThere is an urgentunmet need for novel therapeutic approaches that are efficacious against lung cancerRanking first among cancer deaths in the U Sthis disease hasyear relative survival rates of andltMost lung cancers are non small cellNSCLCof casesCurative surgery is not an option for theof NSCLC patients who present with advanced stage III cancerFor these patients chemo radiation therapy ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Validation of Novel Therapeutic Approach for Leptomeningeal Metastases

    SBC: Minnetronix Medical, Inc.            Topic: 102

    ABSTRACT Leptomeningeal Metastases (LM) is a condition in which tumor cells from a primary tumor metastasize, invade the subarachnoid space (SAS) and spread throughout the cerebrospinal fluid (CSF), resulting in seeding along the meninges, brain and spinal cord. LM represents a devastating event of cancer progression. There are 30,000 cases annually and currently no cure, with average survival of ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government